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Background. We recently found regional differences in the
incidence of end-stage renal disease (ESRD) in Japan, which
is generally ethnically homogeneous, suggesting that factors
other than genetic may contribute to the difference. Here, we
examined regional differences in the amounts of expenses spent
on antihypertensives, especially angiotensin-converting en-
zyme (ACE) inhibitors, in our search for an explanation.
Methods. Annually, the Japanese Society for Dialysis Ther-
apy reports the numbers of patients entering maintenance dial-
ysis in each prefecture of Japan since 1982. We used the findings
for 1995 to 2000 to calculate the annual incidence of ESRD in
each of the 11 regions of Japan. In addition, regional differences
in annual amounts paid for antihypertensive drugs, presumably
corresponding to the amounts used, during the same 6 years,
corrected for population, were estimated.
Results. As in our 1982 to 1998 study, the incidence of ESRD
was high in Okinawa, Kyushu, and Shikoku, while low in Ho-
kuriku, Koshinetsu, and Tohoku (P  0.0001) [one-way re-
peated measures analysis of variance (ANOVA)]. We found
regional differences in the corrected sum paid for total anti-
hypertensive drugs, ACE inhibitors and calcium antagonists.
Only ACE inhibitors were negatively correlated with the inci-
dence of ESRD by linear and multiple regression analyses.
Conclusion. The renal protective effects of ACE inhibitors
have been established by results with animal models of progres-
sive nephropathy and large-scale clinical trials. Our epidemio-
logic results for Japan as a whole show the same protective
effects still more convincingly from a different approach.
We earlier reported regional differences within Japan
in the incidence of patients with end-stage renal disease
(ESRD) starting maintenance dialysis therapy [1, 2]. Be-
cause this country, generally speaking, is racially homo-
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geneous, we believe there may be factors other than
genetic that contribute to the difference. Our aim was to
identify such factors. Strict blood pressure control [3, 4],
especially with angiotensin-converting enzyme (ACE) in-
hibitors [5–10], is now the major treatment strategy avail-
able at present in arresting renal failure.
Therefore, when we set out to identify factors related
to the regional differences, we decided to examine the
amounts of money spent for antihypertensives, especially
those paid for ACE inhibitors, in these different regions
within Japan.
METHODS
The annual amount of money paid for antihyperten-
sive drugs prescribed in each of 47 prefectures of Japan
has been compiled by Crecon Research & Consulting,
Inc. (Tokyo, Japan) and is known only for the recent 6
years between 1995 and 2000. For that reason, we ana-
lyzed the annual incidence of ESRD for the prefectures
for the same 6 years starting in 1995. As in our earlier
study [1], the numbers of patients with ESRD entering
maintenance dialysis therapy, either hemodialysis or
peritoneal dialysis, were obtained from reports of the
Japanese Society for Dialysis Therapy [11]. The method
of calculation was as previously reported [1]. In brief,
for each of the 11 regions of Japan (see below), we
calculated annual means (per population of one million)
for the 6 years of the study from 1995 to 2000. This mean
was the average for that region of the number of patients
with ESRD entering dialysis, corrected for population,
every year during the 6 years.
Definition of the 11 regions
The 47 prefectures of Japan have been traditionally
divided into 11 regions with generally homogeneous cul-
tural and socioeconomic activities that differ somewhat
between regions. Details of the division vary slightly;
our definition is previously described [1] as region 1,
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Table 1. Regional differences in annual incidence of end-stage renal disease (ESRD) and usage of antihypertensive agents
Usage of antihypertensive agents yen/person/year
ESRD incidencea Ageda
Region million/year Totala ACE inhibitorsa Calcium antagonistsa Agea years population %
1, Hokkaido 2508 5670130 133020 266050 62.60.5 16.40.5
2, Tohoku 2166 5790100 153030 276040 63.00.2 19.20.4
3, Kanto 2245 4150100 102020 203050 61.60.2 14.20.3
4, Koshinetsu 21210 5010100 123020 247060 63.40.3 19.60.3
5, Hokuriku 2105 4710100 113010 239050 62.70.4 18.70.3
6, Tokai 2324 427070 108010 209030 62.30.2 16.00.4
7, Kinki 2385 419070 101010 208040 62.80.2 15.80.4
8, Chyugoku 2256 460080 112020 233040 63.60.3 20.20.4
9, Shikoku 2616 4920100 116020 247050 62.60.3 20.70.3
10, Kyushu 2646 444080 104010 231040 63.40.2 19.30.3
11, Okinawa 27410 2980140 73020 146080 60.10.3 12.90.4
ACE is angiotensin-converting enzyme. MeanSEM.
aP  0.0001 by ANOVA
Hokkaido; region 2, Tohoku; region 3, Kanto; region 4,
Koshinetsu; region 5, Hokuriku; region 6, Tokai; region 7,
Kinki; region 8, Chyugoku; region 9, Shikoku; region 10,
Kyushu; and region 11, Okinawa. Incorporation of data
based on the prefecture into larger units based on the
region should decrease error due to the influx and efflux
of population that occur across prefectural lines but that
are mostly restricted within a given region.
Possible factors for regional differences in ESRD
We examined some factors that might contribute to
regional differences in ESRD dynamics. Annual values
for the years from 1995 to 2000 were calculated for each
region from those based on prefectures: the amounts of
money paid for all kinds of prescribed antihypertensive
drugs, ACE inhibitors, and calcium-antagonists, all cor-
rected for population, the mean age of patients with
ESRD entering dialysis therapy [11], and the percentage
of people 65 years old or older [12]. The amount paid
for antihypertensive drugs prescribed in each of the 47
prefectures, reported as the annual sales of the major
classes of antihypertensive products by prefecture at the
reimbursed price level (Crecon Research & Consulting,
Inc.), was corrected for population and used to calculate
the amounts paid in the different regions.
Statistical analysis
One-way repeated measures analysis of variance
(ANOVA) was used to compare the incidence of ESRD
and other factors among the different regions. Linear as
well as multiple (stepwise forward) regression analyses
were applied to identify independent factors for the re-
gional differences in the incidence of ESRD. All numeric
results are given as means  SEM, and the level of




Since the annual usage of antihypertensive drugs, in
money basis, in each prefecture was reported only in 6
years from 1995 to 2000, to our knowledge, we examined
the regional difference in the annual ESRD incidence
in these same 6 years as shown in Table 1. The difference
among 11 regions was significant based on ANOVA (P
0.0001). The regional difference in ESRD incidence ob-
tained in the recent 6 years between 1995 and 2000 was
highly correlated with that we reported in 17 years be-
tween 1982 and 1998 (r  0.92, N  11, P  0.0001) [1].
Usage of antihypertensive drugs and regional
differences in ESRD incidence
The sum of antihypertensive drugs (yen per person
per year) prescribed from 1995 to 2000 in money basis
corrected for population significantly differed among 11
regions across Japan in total antihypertensives, ACE
inhibitors, and calcium antagonists (P  0.0001). Linear
regression analysis showed, among antihypertensives,
only the sum of ACE inhibitors in each region had a
negative relationship with the annual incidence of ESRD
(r  0.40, P  0.0009) in corresponding regions (Fig. 1)
(Table 2).
Other factors correlated with regional differences
in ESRD incidence
Neither average age of ESRD patients entering dial-
ysis therapy nor percentage of the population older than
65 years in each region had correlations with the annual
incidence of ESRD. However, percentage of old popula-
tion in each region had significant positive relationships
with sums of total antihypertensives (r  0.67, P 
0.0001), ACE inhibitors (r  0.51, P  0.0001), and
calcium antagonists (r  0.77, P  0.0001) as well as
average age of ESRD patients (r  0.80, P  0.0001).
Average age of ESRD patients in each region also had
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Fig. 1. Relationships of the sums of total anti-
hypertensive drugs, angiotensin-converting en-
zyme (ACE) inhibitors and calcium antagonists
prescribed in money basis corrected for popu-
lation in each region with the annual incidence
of end-stage renal disease (ESRD) in corre-
sponding regions. The number of observations
were 66, because the 11 regions were multiplied
by 6 years. The sum of antihypertensive drugs
was represented in Japanese yen per person
per year.
Table 2. Linear and multiple correlations of usage of antihypertensive drugs and other factors with annual end-stage renal disease (ESRD) incidence
N  66 Linear correlation (correlation coefficient) Multiple regression (standard coefficient)
Multiple correlation coefficient 0.57 (F  15.2, P  0.0001)
Total antihypertensives 0.15 (P  0.24) 0.84 (F  15.7)
ACE inhibitors 0.40 (P  0.0009) 1.13 (F  28.5)
Calcium antagonists 0.15 (P  0.22) 0.10 (F  0.7)
Age 0.12 (P  0.33) 0.03 (F  0.1)
Aged population 0.009 (P  0.94) 0.04 (F  0.1)
ACE is angiotensin-converting enzyme. Significant factors are shown in bold figures.
significant positive relationships with sums of money
spent on total antihypertensives (r  0.64, P  0.0001),
ACE inhibitors (r  0.38, P  0.0015), and calcium
antagonists (r  0.70, P  0.0001).
Multiple regression analysis to identify factors
independently affecting the regional difference
in ESRD incidence
Stepwise forward multiple regression analysis showed
that the sum of ACE inhibitors worked as an indepen-
dently negative factor to reduce the ESRD incidence,
while the sum of total antihypertensive drugs as a posi-
tive factors to increase it (see Table 2). None of the sum
of calcium antagonists, average age of ESRD patients, or
percentage of aged population in each region correlated
with the annual ESRD incidence in multiple regression
analyses.
DISCUSSION
The present study showed a marked regional differ-
ence within Japan in the annual incidence of ESRD
entering maintenance dialysis therapy even for the re-
cent 6 years between 1995 and 2000, similar to that we
previously reported in 17 years between 1982 and 1998
[1]. Once the regional differences in ESRD dynamics
have been established, the factors affecting the differ-
ences must be elucidated. Since the race is relatively
uniform within Japan, the modifiable factors other than
genetic may play an important role in creating the re-
gional differences. If we can identify such factors, the
strategy to prevent renal failure will be strengthened.
Using an ACE inhibitor is now considered one of
the most promising interventions to arrest renal failure
[5–10]. Therefore, in this study, we intended to examine
the relationships between the regional differences in
ESRD dynamics and the prescribed sum of ACE inhibi-
tors. In fact, ACE inhibitors were identified as a signifi-
cant factor to reduce the incidence of ESRD by both
linear and multiple regression analyses. It should be
noted here that despite a similar regional distribution as
ACE inhibitors, calcium antagonists had no significant
relationships with ESRD dynamics, either positively or
negatively, in linear and multiple regression analyses.
This neutral action of calcium antagonists on renoprotec-
tion seemed consistent with other reports [9, 13]. Fur-
thermore, multiple regression analysis showed that in
contrast to ACE inhibitors, acting as an independently
negative factor, the sum of total antihypertensive drugs
worked as an independently positive factor to increase
Usami et al: Maps of ESRD and ACE inhibitors1448
the ESRD incidence. Since the sum of total antihyperten-
sives may reflect the severity of hypertension, this posi-
tive relationship suggests that overall blood pressure
level played a significant role in the progression of renal
failure. Our findings that ACE inhibitors and total anti-
hypertensives worked in opposite directions with each
other in protecting kidneys seemed to characteristically
reveal a renoprotective action of the former.
In Japan, captopril was introduced in 1983 as the first
ACE inhibitor and enalapril in 1986 as the second. Al-
though we showed in the Results section that the regional
difference in ESRD incidence obtained in the recent 6
years between 1995 and 2000 was highly correlated with
the data we reported in 17 years between 1982 and 1998
(r  0.92, N  11, P  0.0001) [1], we know that the
regional difference has changed significantly with time.
When the annual ESRD incidence was compared in
5-year periods between the old phase of 1982 to 1986
and the recent phase of 1996 to 2000, the regional differ-
ence was significantly influenced by phases (an interac-
tion between regional difference and phases using two-
way ANOVA, P  0.0001). Since the ESRD incidence
was increased by approximately three times with time
in 17 years [1], the recent data (1995 to 2000) strongly
influenced the entire data of 17 years, resulting in signifi-
cant correlation despite clear difference in regional dis-
tribution of ESRD incidence between two phases. In
addition, the increase in annual ESRD incidence in the
above 5-year periods during 14 years from older to recent
phases was analyzed in relation with usage of antihyper-
tensives in the recent 5 years (1996 to 2000). Linear
regression analysis showed only ACE inhibitors had sig-
nificant negative correlations with the increase in ESRD
incidence (total antihypertensives, r  0.17, P  0.21;
ACE inhibitors, r0.31, P 0.020; and calcium antago-
nists, r0.24, P  0.077, N  55). Multiple regression
analysis also identified that only ACE inhibitors were
the negative factor independently working to suppress
the increase in the ESRD incidence (multiple correlation
coefficient  0.31, F  5.7, P  0.02, N  55; ACE
inhibitors, r  0.31, F  5.7; total antihypertensives,
r  0.19, F  2.1; and calcium antagonists, r  0.07,
F  0.2). These analyses support our findings that ACE
inhibitors are one of the major factors determining the
regional difference in ESRD dynamics. It remains un-
proved from our approach, however, whether the intro-
duction of ACE inhibitors has in fact delayed the pro-
gression of nephropathy due to lack of enough data for
regional differences in ESRD dynamics in the periods
before introduction of ACE inhibitors.
On the other hand, it has been documented that long-
term treatment is required to fully manifest the renopro-
tective actions of ACE inhibitors [14]. Therefore, there
may be a time lag between the spread of ACE inhibitor
consumption and the emergence of its effects on the
reduction of ESRD. We repeated analyses using ESRD
data in later 3 years (1998 to 2000) and data of antihyper-
tensives in earlier 3 years (1995 to 1997) to examine
time-lag effects. Similarly, as whole data in 6 years (1995
to 2000), ACE inhibitors were identified as a significant
factor to reduce the incidence of ESRD by both linear
and multiple regression analyses (r  0.37, P  0.036,
N  33; multiple correlation 0.37, F  4.8, P  0.036,
r  0.37, F  4.8). Neither total antihypertensives nor
calcium antagonists were significantly correlated with
ESRD dynamics in the 3-year data. Thus, our data in 3
and 6 years both consistently suggest the renoprotective
actions of ACE inhibitors. There might be still other
factors to explain for the regional differences in ESRD
dynamics such as dietary intake of protein and sodium
as well as socioeconomic status. Clearly, much effort will
be required to identify such factors, which will clarify
the strategies to halt the renal failure progression.
ACE inhibitors have been first proposed to arrest the
progression of nephropathy in variety of animal models
including diabetic nephropathy [5] and renal ablation
models [6]. Large-scale clinical trials also showed that
these agents could slow the disease progression in dia-
betic and nondiabetic nephropathies [7, 9, 14–18]. Now,
therefore, ACE inhibitors are recommended in guide-
lines as compelling drugs for hypertensive patients with
renal dysfunction [19, 20]. Our epidemiologic and eco-
logic data confirm from a different approach that ACE
inhibitors are indeed working to arrest renal disease pro-
gression in clinical practice.
CONCLUSION
The present study, relating regional differences be-
tween ESRD dynamics and usage of antihypertensives
in a nationwide population of Japan, on a macro level,
confirmed the renal protective effects of ACE inhibitors,
established by animal models of progressive nephropa-
thies and large-scale clinical trials.
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